AUROBINDO

October 5, 2021

To	To
Listing Department, **NATIONAL STOCK EXCHANGE OF INDIA LIMITED** Exchange Plaza, Bandra Kurla Complex, Bandra (E), **MUMBAI -400 051** **Company Code No. AUROPHARMA**	The Corporate Relations Department **BSE LIMITED** Phiroz Jeejeebhoy Towers, 25th floor, Dalal Street, **MUMBAI -400 001** **Company Code No. 524804**

Dear Sirs,

Sub: News item captioned "Drug makers Glenmark, Aurobindo Pharma recall products in US market"

Ref : NSE letter No. NSE/CM/Surveillance/11180 dated October 4, 2021.
BSE e-mail dated October 4, 2021.

We refer to your email / letter dated October 4, 2021, seeking clarification on the captioned media report.

We hereby confirm on the matter which involved recall of 2,820 bottles of Metoprolol tartrate tablets in the US market, and the recall was done at the pharmacy level.

As the matter was not material in nature, the same did not warrant disclosure to the Stock Exchanges, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Kindly take the above information on record.

Yours faithfully,
For AUROBINDO PHARMA LIMITED

B. Adi Reddy
Company Secretary

AUROBINDO PHARMA LTD. HYDERABAD, INDIA